MY209381A - Anti-axl antibodies and compositions - Google Patents

Anti-axl antibodies and compositions

Info

Publication number
MY209381A
MY209381A MYPI2022004441A MYPI2022004441A MY209381A MY 209381 A MY209381 A MY 209381A MY PI2022004441 A MYPI2022004441 A MY PI2022004441A MY PI2022004441 A MYPI2022004441 A MY PI2022004441A MY 209381 A MY209381 A MY 209381A
Authority
MY
Malaysia
Prior art keywords
compositions
axl antibodies
axl
antibodies
cancer
Prior art date
Application number
MYPI2022004441A
Other languages
English (en)
Inventor
Torben Gjetting
Trine Lindsted
Janus Schou Jakobsen
Randi Westh Hansen
Anton Willer
Anne Worsaae
Eva Maria Carlsen Melander
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MY209381A publication Critical patent/MY209381A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MYPI2022004441A 2020-02-28 2021-02-26 Anti-axl antibodies and compositions MY209381A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062982852P 2020-02-28 2020-02-28
PCT/IB2021/051636 WO2021171257A1 (en) 2020-02-28 2021-02-26 Anti-axl antibodies and compositions

Publications (1)

Publication Number Publication Date
MY209381A true MY209381A (en) 2025-07-04

Family

ID=75426640

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2022004441A MY209381A (en) 2020-02-28 2021-02-26 Anti-axl antibodies and compositions

Country Status (17)

Country Link
US (1) US11807688B2 (https=)
EP (1) EP4110824A1 (https=)
JP (1) JP7748377B2 (https=)
KR (1) KR20220148237A (https=)
CN (1) CN115210263A (https=)
AR (1) AR121441A1 (https=)
AU (1) AU2021225490B2 (https=)
BR (1) BR112022015977A2 (https=)
CA (1) CA3170975A1 (https=)
CL (1) CL2022002259A1 (https=)
CO (1) CO2022012159A2 (https=)
IL (1) IL295596A (https=)
MX (1) MX2022010670A (https=)
MY (1) MY209381A (https=)
PE (1) PE20221783A1 (https=)
PH (1) PH12022552041A1 (https=)
WO (1) WO2021171257A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026001894A1 (zh) * 2024-06-24 2026-01-02 上海医药集团生物治疗技术有限公司 靶向axl的嵌合抗原受体及其用途
CN119591720B (zh) * 2024-11-28 2026-02-10 北京大学深圳研究生院 抗人axl抗体、基因及其应用
CN119912586B (zh) * 2024-12-31 2025-09-30 四川省肿瘤医院 基于受体酪氨酸激酶家族axl改造的嵌合抗原受体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
CA2706549A1 (en) * 2007-11-15 2009-05-22 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody capable of binding to anexelekto, and use thereof
BRPI1013428A2 (pt) * 2009-05-11 2019-07-02 U3 Pharma Gmbh anticorpos humanizados para axl
BR112012027995A2 (pt) * 2010-06-18 2017-01-10 Genentech Inc anticorpo e ácido nucleíco isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de um indivíduo com câncer, de um indivíduo possuíndo um distúrbio imune, de inibição da angiogênese e para inibir a ativação constitutiva de axl
MX2015005757A (es) * 2012-11-08 2015-11-18 Hoffmann La Roche Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
GB201410826D0 (en) * 2014-06-18 2014-07-30 Bergenbio As Anti-axl antibodies
JP6931609B2 (ja) 2014-12-18 2021-09-08 ベルゲン テクノロジオーヴァーフォリング エイエス 抗Ａｘｌアンタゴニスト抗体
CN108368171A (zh) * 2015-07-10 2018-08-03 根马布股份公司 用于癌症治疗的axl特异性抗体-药物缀合物
PL3368572T3 (pl) * 2015-10-02 2022-09-12 Symphogen A/S Przeciwciała anty-PD-1 oraz kompozycje
TN2018000333A1 (en) * 2016-04-12 2020-01-16 Symphogen As Anti-tim-3 antibodies and compositions
GB201610902D0 (en) * 2016-06-22 2016-08-03 Bergen Teknologioverforing As And Bergenbio As Anti-Axl Antagonistic Antibodies
CA3095986A1 (en) 2018-04-10 2019-10-17 Genmab A/S Axl-specific antibodies for cancer treatment

Also Published As

Publication number Publication date
PH12022552041A1 (en) 2023-11-29
BR112022015977A2 (pt) 2022-10-11
PE20221783A1 (es) 2022-11-16
WO2021171257A1 (en) 2021-09-02
CN115210263A (zh) 2022-10-18
EP4110824A1 (en) 2023-01-04
MX2022010670A (es) 2022-09-23
KR20220148237A (ko) 2022-11-04
AR121441A1 (es) 2022-06-08
IL295596A (en) 2022-10-01
AU2021225490B2 (en) 2025-11-27
CA3170975A1 (en) 2021-09-02
US11807688B2 (en) 2023-11-07
JP7748377B2 (ja) 2025-10-02
CL2022002259A1 (es) 2023-04-14
TW202146455A (zh) 2021-12-16
JP2023515821A (ja) 2023-04-14
CO2022012159A2 (es) 2022-10-31
AU2021225490A1 (en) 2022-09-15
US20210269532A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
MY207784A (en) Anti-cd73 antibodies
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
MY190324A (en) Anti-pd-1 antibodies and compositions
NZ752044A (en) Anti-lag-3 antibodies and compositions
PH12022551013A1 (en) Pyridazinones as parp7 inhibitors
JOP20230030A1 (ar) بنيات RNAi وطرق لتثبيط التعبير عن MARC1
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2020013348A (es) Anticuerpos biespecificos contra dll3-cd3.
MY209381A (en) Anti-axl antibodies and compositions
MX2018015683A (es) Composiciones y métodos para el agotamiento de células.
GEAP202114828A (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
MX2021014193A (es) Moleculas de enlace biespecificas anti-ror1/anti-cd3.
MX2018015684A (es) Composiciones y metodos para el agotamiento de celulas cd117.
UA130700C2 (uk) Поліспецифічні антитіла, що містять тільки важкі ланцюги, з модифікованими константними областями важкого ланцюга
SA520412450B1 (ar) C9orf72 تركيبات لتعديل التعبير الوراثي عن
ZA202211667B (en) Multispecific heavy chain antibodies with modified heavy chain constant regions
EA201691384A2 (ru) Конструкции варианта sirp-альфа и их применение
EA202092518A1 (ru) Композиции и способы лечения рака
MX2022015169A (es) Constructos de arni para inhibir la expresion de hsd17b13 y metodos de uso de los mismos.
MX2023008701A (es) Quinolinas y azaquinolinas como inhibidores de cumulo de diferenciacion 38 (cd38).
PH12023553123A1 (en) Anti-nkg2a antibodies and compositions
MX2023010594A (es) Metodo para el tratamiento contra enfermedades mediante el uso de antagonistas de gremlina 1.
ZA202403747B (en) Compounds and their uses as gpr183 inhibitors
MX2021011040A (es) Anticuerpos dirigidos contra c5ar.